Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 14/20 | 0.36 |
| ▸ | LIMK2 | P53671 | 13/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | LATS1 | O95835 | 1/20 | 0.32 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.32 |
| ▸ | TESK1 | Q15569 | 1/20 | 0.30 |
| ▸ | TESK2 | Q96S53 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15626293 | 1.00 | LIMK1 (0.36) | LIMK1LIMK2HRH3MAPK14LATS1 | |
| SCHEMBL4019003 | 0.89 | LIMK1 (0.38) | LIMK1LIMK2MAPK14LATS1LATS2 | |
| SCHEMBL4018434 | 0.89 | LIMK1 (0.38) | LIMK1LIMK2MAPK14LATS1LATS2 | |
| SCHEMBL4017708 | 0.89 | LIMK1 (0.38) | LIMK1LIMK2MAPK14LATS1LATS2 | |
| SCHEMBL16989342 | 0.88 | FFAR1 (0.36) | LIMK1MAPK14ESR1 | |
| SCHEMBL15626286 | 0.88 | FFAR1 (0.36) | LIMK1MAPK14ESR1 | |
| SCHEMBL4018558 | 0.86 | LIMK1 (0.37) | LIMK1LIMK2HRH3ESR1 | |
| SCHEMBL5538104 | 0.84 | LATS1 (0.34) | LIMK1LIMK2MAPK14LATS1LATS2 | |
| SCHEMBL4020442 | 0.84 | LIMK1 (0.36) | LIMK1LIMK2HRH3ESR1 | |
| SCHEMBL4021324 | 0.84 | LATS1 (0.38) | LIMK1LIMK2MAPK14LATS1LATS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903436-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | UNIV PENNSYLVANIA (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-3219207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | The Trustees Of The University Of Pennsylvania (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-3219207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | The Trustees Of The University Of Pennsylvania (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2017-06-22 | — | — | US | disclosed |
| US-9649317-B2 | Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-05-16 | — | — | US | disclosed |
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | MAPT, PRNP, PSEN2 | LIMK1 1122/4885LIMK2 653/4885HRH3 928/4885 |
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | MAPT, SYNJ1, PARK7 | LIMK1 723/4885LIMK2 601/4885HRH3 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.